Re-examining HSPC1 inhibitors by Lee, SL et al.
Lee, SL and Dempsey-Hibbert, NC and Vimalachandran, D and Wardle, TD
and Sutton, PA and Williams, JHH (2017)Re-examining HSPC1 inhibitors.
Cell Stress and Chaperones, 22 (2). pp. 293-306. ISSN 1355-8145
Downloaded from: http://e-space.mmu.ac.uk/621341/
DOI: https://doi.org/10.1007/s12192-017-0774-0
Please cite the published version
https://e-space.mmu.ac.uk
ORIGINAL PAPER
Re-examining HSPC1 inhibitors
Sheah Lin Lee1,2 & Nina Claire Dempsey-Hibbert1,3 & Dale Vimalachandran4 &
Terence David Wardle4 & Paul A. Sutton4 & John H. H. Williams1
Received: 29 November 2016 /Revised: 3 February 2017 /Accepted: 3 February 2017 /Published online: 2 March 2017
# The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract HSPC1 is a critical protein in cancer development
and progression, including colorectal cancer (CRC).
However, clinical trial data reporting the effectiveness of
HSPC1 inhibitors on several cancer types has not been as
successful as predicted. Furthermore, some N-terminal inhib-
itors appear to be much more successful than others despite
similar underlying mechanisms. This study involved the ap-
plication of three N-terminal HSPC1 inhibitors, 17-DMAG,
NVP-AUY922 and NVP-HSP990 on CRC cells. The effects
on client protein levels over time were examined. HSPC1
inhibitors were also applied in combination with chemothera-
peutic agents commonly used in CRC treatment (5-fluoroura-
cil, oxaliplatin and irinotecan). As HSPA1A and HSPB1 have
anti-apoptotic activity, gene-silencing techniques were
employed to investigate the significance of these proteins in
HSPC1 inhibitor and chemotherapeutic agent resistance.
When comparing the action of the three HSPC1 inhibitors,
there are distinct differences in the time course of important
client protein degradation events. The differences between
HSPC1 inhibitors were also reflected in combination treat-
ment—17-DMAG was more effective compared with NVP-
AUY922 in potentiating the cytotoxic effects of 5-fluoroura-
cil, oxaliplatin and irinotecan. This study concludes that there
are distinct differences between N-terminal HSPC1 inhibitors,
despite their common mode of action. Although treatment
with each of the inhibitors results in significant induction of
the anti-apoptotic proteins HSPA1A and HSPB1, sensitivity
to HSPC1 inhibitors is not improved by gene silencing of
HSPA1A or HSPB1. HSPC1 inhibitors potentiate the cytotox-
ic effects of chemotherapeutic agents in CRC, and this ap-
proach is readily available to enter clinical trials. From a trans-
lational point of view, there may be great variability in sensi-
tivity to the inhibitors between individual patients.
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Introduction
Heat shock proteins (HSPs) are highly conserved molecular
chaperones that prevent proteins from misfolding and aggre-
gation. HSPs are classified into several subgroups or
Bfamilies,^ originally named according to their molecular
weight but now designated based upon sequence homology
(Kampinga et al. 2009). Although first discovered to be up-
regulated upon elevation of temperature, HSPs have distinct
roles in regulating cell functions including proteostasis, apo-
ptosis and carcinogenesis (Hartl et al. 2011; Kennedy et al.
2014; Rappa et al. 2012). Three families of HSPs, HSPC,
HSPA and HSPB, receive special attention in cancer due to
their implications in diagnosis, prognosis and treatment
(Ciocca and Calderwood 2005; Hong et al. 2013).
The HSPC (Hsp90) family is amongst the most abundant
proteins in eukaryotic cells with expression being regulated by
heat shock factor 1 (HSF1) (Csermely et al. 1998; Lindquist
1986). There are two major isoforms of HSPC in the cytoplasm,
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which are the stress-inducible HSPC1 (HSP90AA1/Hsp90α)
and the constitutive HSPC3 (HSP90AB1/Hsp90β) (Chen et al.
2005). HSPC1 particularly plays a fundamental role in the main-
tenance of tumour cell characteristics (Tatokoro et al. 2015).
Along with other HSPs, it is involved in each of the hallmarks
of cancer (Hanahan and Weinberg 2000, 2011) essential for the
development of a malignant phenotype.
HSPC1 are found to be elevated in colorectal cancer (CRC)
cells comparedwith corresponding normal cells (Kanazawa et al.
2003; Milicevic et al. 2008; Liu et al. 2010;Wang et al. 2012). A
wide variety of oncoproteins are chaperoned by HSPC1, main-
taining their stability and function (Citri et al. 2004; Banerji et al.
2008; Azoitei et al. 2012), and in CRC, this is no exception.
HSPC1 stabilisesmutant proteins inmultiple commonly aberrant
pathways contributing to carcinogenesis in CRC (Lee et al.
2015). Consequently, the clinical application of HSPC1 inhibi-
tors in the treatment of CRC may prove beneficial.
Many current anti-cancer treatments are targeted towards a
single specific defect or oncoprotein. Although this can be
successful (Hecht et al. 2009; Flaherty et al. 2010;
Kantarjian et al. 2013), the accumulation of oncogenic muta-
tions during cancer progression may render the treatment in-
effective due to secondary mutations in the target binding
domain and activation of alternative signalling pathways
(Shah et al. 2002; Nazarian et al. 2010). Modulating HSPC1
activity, a protein central to many such signalling pathways,
has therefore become an attractive method to overcome drug
resistance and tumour evolvability. This has led to the devel-
opment of a number of HSPC1 inhibitors, targeting either the
N-terminal or the C-terminal domain (Tatokoro et al. 2015).
Two early N-terminal inhibitors in clinical use were the
g e l d a n amyc i n d e r i v a t i v e s 1 7 - a l l y l am i n o - 1 7 -
d em e t h o x y g e l d a n amy c i n ( 1 7 -AAG ) a n d 1 7 -
dimethylaminoethylamino-17-demethoxygeldanamycin (17-
DMAG). Both of these showed moderate success in clinical
trials, both in isolation and in combination with common chemo-
therapeutic agents (Kim et al. 2009). However, several limita-
tions were evident including hepatotoxicity, solubility issues and
reliance on NAD(P)H:quinone oxidoreductase 1 (Kelland et al.
1999; Ge et al. 2006; Solit et al. 2008). Although theoretically an
attractive strategy, success rates from clinical trials have not been
as predicted. HSPC1 inhibitors showmoderate success as mono-
therapy in lung cancer with ALK re-arrangement and in combi-
nation with transtuzumab in HER2+ breast cancer (Modi et al.
2011; Socinski et al. 2013). As a result, attention was shifted to
the development of small entity, non-geldanamycin derivates
such as NVP-AUY922 and NVP-HSP990 with the aim of im-
proving therapeutic efficacy and reducing toxicity.
Inhibition of HSPC1 function results in degradation of client
proteins including HER2, p-Akt, p-S6, HIF1-α, VEGF and a
consequent reduction in cell viability (Okui et al. 2011).
However, the time course of these degradation events is still
unclear. Furthermore, an additional consequence of HSPC1
inhibition is an increase in the anti-apoptotic proteins HSPA1A
and HSPB1, via de-stabilisation of the HSF1-HSPC1 complex
(Neckers and Workman 2012). Studies that are emerging show
that targeting HSPB1 or HSPA1A enhances cytotoxic effects of
HSPC1 inhibitors (Powers et al. 2008; Lamoureux et al. 2014).
The aim of this study was to determine whether resistance to
chemotherapeutic agents can be overcome by inhibiting the ac-
tivity of this essential chaperone during a period of such intense
cellular stress. In addition, the importance of HSPA1A and
HSPB1 in resistance to HSPC1-induced cell death—and resis-
tance to common chemotherapeutic drugs—was investigated.
This study involved the application of three HSPC1 inhibitors,
17-DMAG, NVP-AUY922 and NVP-HSP990, to CRC cells.
The production of these three inhibitors has been halted for var-
ious reasons including failure to showmeaningful clinical results
and also associated toxicities. Their employment in this study
was as a proof of principle to elucidate the effect that different
HSPC1 inhibitors, with similar modes of action, have on client
proteins that are essential to carcinogenesis. A deeper under-
standing ofHSPC1 inhibitor-induced cellular changes is essential
to drive forward research and development of this class of drug
with the potential to simultaneously target many signalling path-
ways shown to be de-regulated in cancer. Changes in client pro-
tein levels over time were examined, along with the resultant
effects on cell survival, to provide an explanation of why these
inhibitors are not as effective in practice as is predicted theoret-
ically. Cell sensitivity to combination treatments involving these
HSPC1 inhibitors and chemotherapeutic drugs commonly used
in CRC treatment was also analysed.
Methods
Cell culture
HT29 cells (ECACC) were maintained at 37 °C in EMEM
media (Lonza) supplemented with 10% FBS (Lonza) (10%
EMEM) in a humidified environment of 5% CO2 in air.
Cells were routinely passaged when at 90% confluence using
trypsin/EDTA (Lonza).
Drug treatments
A cell density of 3 × 104 cells/well was seeded into 96-well
plates and left to adhere to the plate overnight at 37 °C. 17-
Dimethylaminoethylamino-17-demethoxygeldanamycin (17-
DMAG) (Bioquote, SIH-114A), NVP-AUY922, NVP-
HSP990 (both provided by Novartis), oxaliplatin (OX)
(Sigma, O9512), 5-fluorouracil (5-FU) (Sigma, F6627),
irinotecan (IRN) (Sigma, I1406) and cyclohexamide (CHX)
(Sigma, C4859) were all made up to the appropriate concen-
trations in 10% EMEM and added to the cells for the indicated
times. For combination experiments, HT29 cells were treated
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with 5-FU, OX or IRN for 24 h followed by addition of
HSPC1 inhibitors for 48 h. Concentrations of HSPC1 inhibi-
tors (17-DMAG, NVP-HSP990 and NVP-AUY922) and tra-
ditional chemotherapeutic agents (5-FU, oxaliplatin and
irinotecan) are stated in each figure legend.
Flow cytometry analysis
Following treatments, cells were trypsinised, transferred to
96-well V-bottom plates and centrifuged at 500g for 5 min
to remove trypsin/EDTA to be stained with the appropriate
antibodies. All analysis was performed on a FACS Canto II
flow cytometer (Becton Dickinson).
Caspase-3, HSPA1A and HSPB1 analyses
A 70 μl/well volume of Cytofix/Cytoperm (BD Biosciences)
was added to each well, and the cells were incubated at 4 °C
for 20 min. Following further centrifugation, cells were incu-
bated in 100 μl/well of wash buffer (5% FBS in DPBS) for
15 min at room temperature (RT). Cells were centrifuged
again before addition of 6.7 μl/well of FITC-conjugated an-
ti-human active caspase-3 (BD Biosciences, 559,341), 50 μl/
well of FITC-conjugated anti-human HSPA1A (Bioquote,
SMC-103B) or 50 μl/well of FITC-conjugated anti-human
HSPB1 (Bioquote, SMC161). The HSP antibodies were dilut-
ed 1:50 in wash buffer prior to addition to the wells. Cells
were incubated for 45 min at 4 °C in the dark. A 100-μl
volume of wash buffer was added to the top of the wells to
dilute any unbound antibody before the plate was centrifuged
again. Finally, the cells were re-suspended in 100 μl/well of
DPBS ready for flow cytometry.
Phosphorylated NF-ĸB and HER-2 analyses
Cells were fixed using 100-μl/well volume of 4% paraformal-
dehyde (BD Biosciences), and the cells were incubated at
37 °C for 10 min. Following further centrifugation, cells
intended for phosphorylated NF-ĸB analysis were
permeabilised using 100-μl/well Perm Buffer III (BD
Biosciences, 558,050) and incubated for 30 min at 4 °C.
Following permeabilisation (or immediately following para-
formaldehyde fixation for HER-2 samples), cells were re-
suspended in 100 μl/well of wash buffer for 15 min at RT.
The cells centrifuged again, and 4 μl/well of FITC-conjugated
anti-human HER-2/NEU (BD Biosciences, 340,553) or 50 μl/
well of 1:50 dilution of Alexa-Fluor 488-conjugated anti-
human NF-ĸB (BD Biosciences, 558,421) was added. The
cells were incubated for 45 min at 4 °C in the dark. A
100-μl volume of wash buffer was added to the top of the
wells to dilute any unbound antibody before the plate was
centrifuged again. Finally, the cells were re-suspended in
100 μl/well of DPBS ready for flow cytometry.
Annexin V analysis
Following an additional washing step in DPBS, 50 μl/well of
a 1:20 dilution of FITC-conjugated Annexin V (BD
Biosciences, 556,419) diluted in binding buffer (0.1 M
HEPES/NaOH, 1.4 M NaCl, 25 mM CaCl2) was added to
each well. The plate was incubated in the dark for 20 min.
The cells were analysed immediately by flow cytometry.
Propidium iodide plate-based assay
Following treatments, the supernatant was removed from each
well and 50 μl/well of fresh 10% EMEM was added. A 50-μl
volume of a 5 μg/ml propidium iodide solution (Sigma,
P4170), diluted in DPBS, was added to each well, and the
plate was incubated in the dark for 1 h at RT. The fluorescence
was detected at Ex/Em 535/617 on a HT Synergy fluorescence
plate reader.
MTS assay
The supernatant was removed from each well following treat-
ments, and 100 μl/well of fresh 10% EMEM was added. A
20-μl volume of a MTS solution (Promega, G1112) was
added to each well, and the plate was incubated in the dark
for 1 h at 37 °C. The absorbance was detected at 490 nm on a
Synergy HT plate reader.
Western blotting
Western blots were performed on cell extracts from HT29.
Protein concentrations of extracts were determined by
Uptima CooAssay Max Protein Assay Kit (Interchim,
UP87542A) to ensure equal loading. Proteins were separated
by electrophoresis on 12.5% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) for HSPB1 de-
tection and 10% SDS-PAGE for HSPA1A detection. HSPB1
(StressMarq, SPR-105B) and HSPA1A (StressMarq, SPR-
103B) human recombinant proteins were used as standard
controls. Separated proteins were transferred onto nitrocellu-
lose membranes using a Bio-Rad Trans-Blot Turbo Transfer
System. HSPB1 was detected using a monoclonal HSPB1
antibody (StressMarq, SMC-161A) at 1:5000 dilution as the
primary antibody and anti-mouse IgG–peroxidase (Sigma-
Aldrich, A5278) at 1:2000 as the secondary antibody.
HSPA1Awas detected by HSPA1A-DEG-EI (in house) dilut-
ed at 1:2000 as the primary antibody and ExtraAvidin®-
Peroxidase (Sigma-Aldrich, E2886) diluted 1:5000 as second-
ary antibody. Membranes were washed with TBS-Tween 20
and then incubated for 5 min in SuperSignal West Femto
Maximum Sensitivity (Thermo Scientific) substrate.
Chemiluminescence was detected using the ChemiDoc MP
detection system (Bio-Rad, Hercules, CA, USA).
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Small interfering RNA transfection
Cells were seeded at a density of 3 × 104 cells/well in 96-well
tissue culture plates the day before the experiment. The fol-
lowing day, EMEM was removed from the cells (plate 1) and
100 μl of new EMEM was added to each well. A lipid-based
transfection method was used to transfect cells with small
interfering RNAs (siRNAs). For each well, 1.4 μl of the trans-
fection reagent, lipofectamine 2000 (Life Technologies,
11,668–027), was diluted in 25 μl of optiMEM (Life
Technologies, 31,985), and the solution was applied to a fresh
96-well plate. For each well, a 0.4-μl volume of the respective
siRNAs (Dharmacon, M-005168-01-0020 andM-005269-01-
0020) was diluted in 25 μl optiMEM and combined with the
lipofectamine 2000 solution in the new 96-well plate. This
plate was then incubated at RT for 20 min on a plate shaker
to allow the lipofectamine and siRNAs to form complexes.
After 20 min, the lipofectamine-siRNA solution (50 μl/well)
was transferred directly to the corresponding wells containing
HT29 cells in the original 96-well plate (plate 1). The cells
were then incubated at 37 °C for 24 h before further treat-
ments. In all experiments involving siRNA, control samples
treated with (a) transfection agent only, (b) non-targeting
siRNA (Dharmacon, D-001210-01-20) and (c) RISC-free
siRNA (Dharmacon, D-001220-01-20) were included.
Statistical analysis
Statistical analyses were performed using PRISM version 5.0.
An unpaired t test or a one-way ANOVAwith a Dunnett’s post
hoc test was used as indicated. Statistical significance was
considered when p < 0.05, and significance levels are indicat-
ed on the figures; * represents p < 0.05, ** represents p < 0.01
and *** represents p < 0.001.
Results
CRC cells show differential sensitivity to HSPC1
inhibitors
HT29 cells were treated with varying concentrations of the
HSPC1 inhibitors 17-DMAG, NVP-AUY922 and NVP-
HSP990 for 48 h. Apoptosis, necrosis and cellular biochemi-
cal activity were assessed using the caspase-3, PI and MTS
assays, respectively. A significant increase in caspase-3 levels
was observed following 125-nM treatment with 17-DMAG
and NVP-HSP990, whilst NVP-AUY922 had no effect even
at 2 μM concentrations (Fig. 1a). Significant PI uptake was
not observed (Fig. 1b) following any of the inhibitors. MTS
assay showed a significant decrease in biochemical activity
and hence cell survival following treatment with nanomolar
concentrations of 17-DMAG and NVP-HSP990 but not NVP-
AUY922 (Fig. 1c). Bright field microscopy of the cells
highlighted the drug resistance displayed by HT29 cells to
NVP-AUY922 and their sensitivity to 17-DMAG and NVP-
HSP990 (Fig. 1d). Taken together, the results indicate that 17-
DMAG and NVP-HSP990 induce cytostasis and cell death in
HT29 cells via apoptosis and not via necrosis. HT29 cells
appear to be resistant to NVP-AUY922.
HSPC1 inhibitors act to de-stabilise HSPC1 client proteins
at an early stage of treatment
Levels of HER-2 and pNF-ĸB (p65 subunit) were analysed in
HT29 cells over the course of treatment with 1-μM HSPC1
inhibitor. HER-2 levels were significantly reduced following
just 2 and 3 h of treatment with 17-DMAG andNVP-HSP990,
respectively, and continued to decrease throughout the course
of 48-h treatment (Fig. 2a). Despite the drug resistance ob-
served earlier, levels of this HSPC1 client protein were also
significantly reduced in NVP-AUY922-treated cells during
early-stage treatment. However, following 6-h treatment with
NVP-AUY922, HER-2 levels began to increase and returned
to pre-treatment values at 48 h (Fig. 2a). In comparison, the
level of pNF-ĸB, a protein indirectly regulated by HSPC1 via
its interaction with IĸK, was unaffected by any of the inhibi-
tors for the first 12 h of treatment (Fig. 2b). Levels did de-
crease however following 24-h treatment with 17-DMAG,
NVP-HSP990 and to a lesser degree NVP-AUY922.
As predicted, due to de-stabilisation of the HSF1-HSPC1
complex, levels of HSPA1A (Fig. 2c) and HSPB1 (Fig. 2d)
were significantly increased following 3-h treatment with all
three inhibitors, including NVP-AUY922. 17-DMAGwas the
most effective at sustaining an increase in HSPA1A levels,
maintaining a fivefold increase above baseline at 48 h. NVP-
HSP990 and NVP-AUY922 were also able to stimulate a
threefold increase in HSPA1A within 12 h, which decreased
after 24 h. 17-DMAG had stimulated a fourfold increase in
HSPB1 above baseline levels at 24 h, which was reversed at
48 h. NVP-AUY922 treatment also resulted in a sudden four-
fold increase at 10 h followed by a decline similar to that
observed after 17-DMAG treatment. In contrast, NVP-
HSP990 treatment resulted in a much more gradual increase
in HSPB1 which eventually decreased after 24 h. These
changes in HSPB1 levels highlight the differences in cellular
response induced by each inhibitor, despite the similar modes
of action, as mentioned above. Flow cytometry data showed
that HSPA1A was induced to a much greater extent than
HSPB1 following HSPC1 inhibitor treatment. The stimulating
effects of these inhibitors on HSPB1 and HSPA1A were fur-
ther confirmed using western blotting, although differences
between the two proteins were not as prominent when
analysed using this less sensitive technique (Fig. 2, inset).
Examining the early apoptotic state of HT29 cells during
inhibitor treatment (Fig. 2e), using Annexin V time-course
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analysis, showed that although phosphatidylserine (PS) levels
increased significantly following all three inhibitors, it began
to decrease after 6 h of NVP-AUY922 treatment. This time
point coincided with the time point when NVP-AUY922
started to lose its HER-2 degradation ability (Fig. 2a), suggest-
ing that the poor cytostatic and cytotoxic effects of NVP-
AUY922 might be related to its inability to degrade client
proteins.
The increase in HSPA1A and HSPB1 in response
to HSPC1 inhibition is due to protein synthesis as opposed
to re-localisation of existing protein
HT29 cells were treated with CHX, an inhibitor of protein
translation prior to 17-DMAG treatment. As expected, levels
of HSPA1A (Fig. 3a) and HSPB1 (Fig. 3b) were significantly
increased following 17-DMAG-only treatment whilst prior
treatment with CHX prevented the induction of these proteins,
confirming that HSPA1A and HSPB1 induction is not due to
re-localisation of existing proteins to the cytoplasm.
HSPC1 inhibitors potentiated the effect
of chemotherapeutic agents
The potential for sensitising CRC cells to the chemotherapeu-
tic agents 5-FU, OX and IRN using HSPC1 inhibitors was
tested. Dose-response experiments (data not shown) deter-
mined the concentrations of chemotherapeutic agents to be
used. Non-toxic concentrations were used so that any sensiti-
sation could be successfully observed.
When combined with 5-FU, 17-DMAG and NVP-HSP990
were able to significantly decrease cell metabolism by a fur-
ther 20% compared to single agent treatment (Fig. 4a). In
contrast, no sensitisation to 5-FU was observed following
combined treatment with NVP-AUY922. When looking at
apoptosis in these cells, 17-DMAG was able to further in-
crease 5-FU-induced apoptosis significantly, whilst NVP-
AUY922 did not potentiate the cytotoxic effect of 5-FU
(Fig. 4b). Caspase-3 levels appeared to be lower in combina-
tion treatments involving NVP-HSP990 than either agent
alone, but this is presumably due to induction of late-stage
apoptosis when concentrations of these effector caspases be-
gin to reduce (Fig. 4b). 17-DMAG and NVP-HSP990 were
also able to potentiate the cytostatic effect of OX (Fig. 4c) and
increased the degree of apoptosis by approximately twofold
when compared with OX in isolation (Fig. 4d). Again, NVP-
AUY922 was unable to replicate this same potentiation.
Sensitisation effects of these inhibitors on IRN were not as
pronounced as with 5-FU and OX. Only 17-DMAG showed
a significant effect on potentiating the effects of IRN when
biochemical activity was analysed (Fig. 4e), yet when
caspase-3 levels were analysed, both 17-DMAG and NVP-
Fig. 1 a Caspase-3. b Propidium
iodide. cMTS assays on HT29
cells treated with HSPC1
inhibitors (0–2 μM) for 48 h. d
Bright field microscopy at ×40
magnification on HT29 cell
treated with HSPC1 inhibitors
(1 μM) for 48 h. Data in a, b and c
are presented as mean ± SEM.
Statistical analysis was performed
using the one-way ANOVAwith
Dunnett’s post hoc test
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HSP990 were able to sensitise cells to IRN-induced apoptosis
(Fig. 4f). This suggests that the effects are more cytotoxic than
cytostatic. Again, NVP-AUY922 did not have any effect on
either the cytostatic or cytotoxic effects of irinotecan.
Inset:
C: Untreated control
DM: 17-DMAG
HSP: NVP-HSP990
AUY: NVP-AUY922
Fig. 2 Time course analysis of a HER-2, b pNF-kB, c HSPA1A, d
HSPB1 and e Annexin V, in HT29 cells treated with HSPC1 inhibitors
(1 μM) for 48 h. Data are presented as mean ± SEM. Statistical analysis
was performed using the one-way ANOVAwith Dunnett’s post hoc test.
The inset denotes the Western blots for HSPB1 and HSPA1A following
48 h of HSPC1 inhibitor treatment (1 μM)
Fig. 3 a HSPA1A and b HSPB1 analyses in HT29 cells treated with
CHX (2.5 μg/ml) for 1 h before addition of 17-DMAG (1 μM) for
24 h. CHX remained on the cells throughout the 17-DMAG treatment
period. Data are presented as absolute mean fluorescence intensity (MFI)
values. Statistical analysis was performed using the unpaired t test
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Sensitivity to HSPC1 inhibitors is not heavily reliant
upon HSPA1A or HSPB1 levels
The increase in anti-apoptotic HSPA1A and HSPB1 levels
in response to HSPC1 inhibitor treatment could be counter-
productive, hindering the cytotoxic effects of HSPC1 in-
hibitors. Therefore, HSPA1A and HSPB1 genes were si-
lenced using lipid-based siRNA transfection techniques
prior to treatment with HSPC1 inhibitors, and protein
levels along with caspase-3 levels were analysed. 17-
DMAG was used as a representative HSPC1 inhibitor
and, as expected, resulted in a significant induction of both
HSPA1A and HSPB1 at the concentration of 300 nM used
in the previous set of experiments (Fig. 5a, b). Gene
silencing of HSPA1A (Fig. 5a) and HSPB1 (Fig. 5b)
showed a significant decrease in protein levels from base-
line levels, whilst control siRNAs did not affect these pro-
teins, indicating effective and specific knockdown. When
cells were treated with 17-DMAG following siRNA-
mediated knockdown of HSPA1A (Fig. 5a), there was
greater than a fourfold reduction in HSPA1A protein when
compared to protein levels in cells treated with 17-DMAG
in isolation. Similarly, knockdown of HSPB1 prior to treat-
ment with 17-DMAG reduced HSPB1 protein levels by
fivefold, when compared to levels observed in 17-
DMAG-only-treated cells (Fig. 5b). Treating cells with
17-DMAG following transfection with control siRNAs
did not affect the levels of HSPA1A or HSPB1 protein
Fig. 4 HT29 cellular metabolism
(a, c, e) and caspase-3 analysis (b,
d, f) following treatment with
12.5 μM5-FU (a, b), OX (c, d) or
IRN (e, f) for 24 h followed by
different HSPC1 inhibitors
(300 nM) for a further 48 h. Data
are presented as percentage of cell
metabolism and percentage in-
crease in caspase-3 compared to
the control (untreated) population.
Statistical analysis was performed
using the unpaired t test
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when compared to 17-DMAG-only treatment, again,
highlighting the specific nature of the gene silencing.
Caspase-3 analysis in these cells revealed that silencing of
HSPA1A prior to 17-DMAG treatment increased the level of
apoptosis from 35% in 17-DMAG-only-treated cells to 50%
(Fig. 5c), whilst similar knockdown of HSPB1 also caused a
small but significant sensitisation to 17-DMAG treatment. As
expected, caspase-3 levels were not significantly different in
cells transfected with the control siRNAs prior to 17-DMAG
treatment when compared with 17-DMAG treatment alone,
suggesting that it is the specific knockdown of HSPA1A or
HSPB1 causing the increased drug sensitivity rather than
merely the process of siRNA transfection. However, given
the substantial decrease in the anti-apoptotic HSPA1A or
HSPB1 proteins using this technique, observing such a
small increase in drug sensitivity is somewhat unexpected.
Similar experiments using NVP-HSP990 demonstrated
that knockdown of HSPA1A prior to NVP-HSP990 treat-
ment causes a small but significant increase in caspase-3
levels compared to those levels seen in NVP-HSP990-
only-treated cells. In contrast, silencing of HSPB1 did not
sensitise cells to NVP-HSP990 (Fig. 5c). Although
silencing of HSPB1 but not HSPA1A prior to NVP-
AUY922 treatment resulted in a small increase in
caspase-3 levels when compared to NVP-AUY922 treat-
ment alone, HT29 cells continued to show resistance to
this HSPC1 inhibitor, with only a 2% increase in caspase-
3 levels above control following the double treatments
(Fig. 5c).
Gene silencing of HSPB1, but not HSPA1A, potentiated
the effects of 5-FU and OX
To determine whether HSPB1 or HSPA1A are important in
determining sensitivity to mainstream chemotherapeutic
agents used in CRC treatment, siRNA transfection techniques
were used as before to knockdown prior to treatment with 5-
FU, OX and IRN.
Cell survival decreased by approximately 30% after 5-FU
treatment of HSPB1-knockdown HT29 cells, when compared
with 5-FU treatment alone (Fig. 6a). There was, however, no
difference in metabolism when HSPA1A gene was silenced
instead (Fig. 6a), suggesting that HSPB1 may be more impor-
tant in conferring drug resistance to 5-FU. A similar picture
Fig. 5 a HSPA1A, b HSPB1 and c caspase-3 analyses in HT29 cells
following siRNA-mediated gene silencing prior to HSPC1 inhibitor treat-
ment. Cells were treated with siRNA for 24 h before addition of HSPC1
inhibitor (300 nM) to the culture medium for a further 48 h.
Lipofectamine only (Lipo), non-targeting siRNA (NT) and RISC-free
siRNA (RF) were used as controls to ensure specific knockdown of
HSPA1A or HSPB1. HSPA1A and HSPB1 data are presented as
percentage change from levels expressed by untreated cells. Caspase-3
data is presented as percentage of cells that are positive for caspase-3 after
48 h. Statistical analysis was performed using the unpaired t test to com-
pare inhibitor-only treatment with the corresponding inhibitor plus
siRNA
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was observed with OX treatment, as caspase-3 levels were
significantly higher following OX treatment of HSPB1
knockdown, but not HSPA1A knockdown HT29 cells versus
OX-treated cells only (Fig. 6b). Conversely, the cytotoxic ef-
fects of IRN were not affected by prior silencing of either
HSPB1 or HSPA1A (Fig. 6c).
Serial re-application of NVP-AUY922 results in increased
HSPC1 client protein degradation and cell sensitivity
to chemotherapy
So far, HT29 cells have shown resistance to NVP-AUY922,
both when applied in isolation and when applied in combina-
tion with chemotherapeutic drugs. The effects of this HSPC1
inhibitor on client protein levels appear to be transient.
Therefore, the effect of re-applying NVP-AUY922 every 6 h
throughout the entire treatment duration was investigated.
Interestingly, increasing the number of re-applications over
the 24-h period significantly reduced the levels of HER-2
(Fig. 7a). Furthermore, when cells were treated with a combi-
nation of OX and NVP-AUY922, where NVP-AUY922 was
re-applied at regular time intervals, increasing the number of
re-applications resulted in a significant decrease in cell surviv-
al with only 30% of cells surviving five re-applications
(Fig. 8). However, the cytostatic effect is still inferior when
compared to OX in combination with a single dose of 17-
DMAG (Fig. 8).
Discussion
HSPC1 inhibitors elicit different responses in the same
CRC cell line
HSPC1 inhibition in anti-cancer therapy has been well stud-
ied, and a number of clinical trials have been carried out using
both N-terminal and C-terminal inhibitors on a variety of can-
cer cell types (Hong et al. 2013). Yet, most trials report a
Fig. 6 Cell survival analysis analysed by caspase-3 or MTS assay in
HT29 treated with HSPB1 or HSPA1A siRNA for 24 h followed by
12.5 μM of a 5-FU, b OX or c IRN for a further 48 h. Statistical
analysis was performed using the unpaired t test to compare
chemotherapeutic drug alone with the corresponding drug + siRNA-
treated samples
Fig. 7 HER-2 levels in HT29 cells treated for 24 h with 1 μM NVP-
AUY922 or for comparison, 17-DMAG. NVP-AUY922 was re-applied
at varying time intervals during the 24-h period. Twenty-four-hour
treatment with NVP-AUY922, no re-application (1). NVP-AUY922
was re-applied at t = 6 and left for the remaining 18 h (2). NVP-
AUY922 was re-applied at t = 6 and t = 12 and left for the remaining
12 h (3). NVP-AUY922 was re-applied at t = 6, t = 12 and t = 18 and left
for the remaining 6 h (4). Statistical analysis was performed using
unpaired t test to compare percentage changes in HER-2 after various
treatment to control (untreated) population
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modest response at best to these treatments, and despite very
similar mechanisms of action between some inhibitors, there
are differences in response rates. The time course of events
involving inhibitor interaction with the ATP-binding pocket of
HSPC1 and consequent release and degradation of the HSPC1
client (Blagg and Kerr 2006) is unclear and will undoubtedly
differ between cancer cell types and between inhibitors.
Different responses to HSPC1 inhibitors have been reported
in the literature but little attention has been paid to this obser-
vation, and its clinical relevance has not been explored. The
current study have showed that in the same cell line (HT29), it
is possible to be simultaneously susceptible and resistance to
the same class of N-terminal HSPC1 inhibitor with similar
underlying mechanism.
This differential sensitivity to N-terminal inhibitors has
been reported in other studies, although they reported resis-
tance to geldanamycin derivatives and concomitant sensitivity
to NVP-AUY922 (Gaspar et al. 2009; Mayor-López et al.
2014; Kim et al. 2015). Niewidok et al. (2012) used the same
concentration of NVP-AUY922 and NVP-BEP800, also an
HSPC1 inhibitor, and showed distinct difference in plating
efficacy as well as Akt and Raf-1 degradation in lung and
glioblastoma cell lines. Thus far, clinical trials are designed
to use only one type of HSPC1 inhibitor. However, it is pos-
sible based on the findings in this study that patients who are
resistant to one HSPC1 inhibitor could respond to another.
This does raise the next question that needs to be addressed,
what is the mechanism of resistance to HSPC1 inhibitors?
Resistance to NVP-AUY922 is likely associated with an
inability to sustain HSPC1 client protein degradation
The results from the present study suggest that the cytotoxic
and cytostatic effects of 17-DMAG and NVP-HSP990 are
directly associated with their ability to maintain decreased
levels of HSPC1 client proteins. Initial decreases in HER2
and NF-ĸB and concomitant increases in HSPA1A and
HSPB1 were observed after treatment with all three HSPC1
inhibitors. However, a striking difference in the time course of
client-degradation events following NVP-AUY922 treatment
compared to that of 17-DMAG and NVP-HSP990 can be
observed after 6–8 h. In particular, the decrease in HER-2
following NVP-AUY922 is seen to be transient, with the level
of HER-2 returning to baseline level after 48 h of treatment.
These results confirm that the function of HSPC1 inhibitor is
mediated through its ability to degrade client proteins and
support the findings published in the literature (McLaughlin
et al. 2006; Okui et al. 2011; Lee et al. 2011).
Increasing the concentration of NVP-AUY922 applied to
the HT29 cells did not overcome this resistance (Fig. 1), yet
repeated application of NVP-AUY922 on HT29 cells over a
24-h period resulted in a sustained decrease in client protein
levels and a sensitisation to low-dose OX (Fig. 8), an effect
that has not been previously investigated. It could be
hypothesised that the NVP-AUY922’s affinity for HSPC1 is
lower than that of 17-DMAG and NVP-HSP990 in CRC cells,
and as a result, it is unable to effectively compete with HSPC1
clients for the HSPC1 ATP-binding site. In agreement with
these findings, NVP-HSP990 has been found to be more ef-
fective at inducing HSPA1A expression in neuroendocrine
carcinoid cells than NVP-AUY922 treated with the same
doses, although IC50 values were higher for NVP-HSP990
(Zitzmann et al. 2013). The time course of events was moni-
tored up to 144 h in that study, so extending the treatment
duration in the present system may have allowed sufficient
time to see NVP-AUY922-associated toxicity. In a study ex-
amining the NVP-AUY922-induced degradation of HSPC1
clients in glioblastoma cell lines, effects on some client pro-
teins were seen to be more transient compared to 17-AAG
treatment, supporting the results shown here (Gaspar et al.
2010).
17-DMAG and NVP-HSP990 potentiated the effects of 5-FU,
OX and IRN
By targeting HSPC1 during conventional chemotherapeutic
treatment, it is proposed that normal cell signalling is
disrupted, and hence, cells show increased susceptibility to
the chemotherapeutic agent. By treating with chemotherapeu-
tic agents first, cells become stressed and ultimately more
reliant on HSPs for survival. Subsequent treatment with a
HSPC1 inhibitor, in theory, should enhance the cytotoxic
Fig. 8 MTS assay onHT29 cells following combined treatment with OX
(25 μM) and NVP-AUY922 (300 nM) and for comparison, 17-DMAG
(300 nM). OX was applied in isolation for the first 24 h, and NVP-
AUY922/17-DMAG was added to the culture media for a further 48 h.
NVP-AUY922 was re-applied at specific time intervals over the 48-h
period. Forty-eight-hour treatment with NVP-AUY922, no re-
application (0). NVP-AUY922 was re-applied at t = 6 and left for the
remaining 42 h (1). NVP-AUY922 was re-applied at t = 6 and t = 12 and
left for the remaining 36 h (2). NVP-AUY922 was re-applied at t = 6,
t = 12 and t = 24 and left for the remaining 24 h (3). NVP-AUY922 was
re-applied at t = 6, t = 12, t = 24 and t = 32 and left for the remaining 16 h
(4). NVP-AUY922 was re-applied at t = 6, t = 12, t = 24, t = 32 and t = 40
and left for the remaining 8 h (5). Statistical analysis was performed using
the one-way ANOVA with Dunnett’s post hoc test, and significant
differences from the BOX only^ are indicated
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effects of the drug. In the present study, both 17-DMAG and
NVP-HSP990 potentiated the effects of low-dose 5-FU and
OX, and 17-DMAG was also found to enhance the effects of
low-dose IRN. The findings are similar to those reported by
He et al. (2014), who showed potentiation of capecitabine
activity, a 5-FU pro-drug, using the HSPC1 inhibitor
ganetespib in HCT116 CRC cells. Additive effects of 17-
AAG and SN-38, the active metabolite of IRN, have also been
reported in p53-null HCT116 cells (Tse et al. 2009). NVP-
HSP990 has also shown synergy when used in combination
with melphalan in multiple myeloma cells, inducing signifi-
cantly more apoptosis than that induced by either agent alone
(Lamottke et al. 2012).
In line with the observed resistance following single appli-
cation of NVP-AUY922, this inhibitor was unable to enhance
the cytotoxicity of 5-FU, OX or IRN in HT29. This is ex-
plained by the ability of the HSPC1 client proteins to return
to baseline levels during single-dose treatment, and therefore,
normal cell signalling is restored. However, NVP-AUY922
was able to show activity in other cell lines when combined
with chemotherapeutic agents such as temsirolimus in oral
squamous cell carcinoma and cytarabine in acute myeloid
leukaemia (Okui et al. 2013; Wendel et al. 2016). Therefore,
the application of NVP-AUY922 in CRC should be further
investigated in other cell lines or xenograft models which may
show positive results.
HSPA1A and HSPB1 play a role in chemosensitivity
to HSPC1 inhibitors and mainstream CRC agents
A hallmark of HSPC1 inhibition is the degradation of the
HSPC1-HSF1 complex and resultant HSPA1A (and HSPB1)
expression which may attenuate inhibitor treatment
(Davenport et al. 2010). This study shows that siRNA-
mediated silencing of these genes prior to HSPC1 inhibitor
treatment was successful at suppressing the induction of
HSPA1A and HSPB1. However, despite highly significant
decreases in protein levels, the effect on HSPC1-inhibitor-
induced apoptosis was only modest, yet statistically signifi-
cant, suggesting that induction of these proteins following
inhibitor treatment may not be as hampering as predicted.
However, only a single gene was silenced in any given sam-
ple. Silencing of HSPB1, for example, may result in a com-
pensatory effect by HSPA1A or other HSPs. Future dual-
silencing techniques prior to inhibitor treatment may reveal a
greater role for these proteins in cytoprotection. The results
support findings by Powers et al. (2008), who reported that
silencing of HSPA1A did not sensitise HCT116 cells to 17-
AAG, yet dual silencing of HSPA1A and HSPA8 (Hsc70)
showed significant potentiation.
HSPA1A and HSPB1 have both been implicated in
chemoresistance towards 5-FU in CRC (Grivicich et al.
2007; Tsuruta et al. 2008; Ang et al. 2010), whilst Choi
et al. (2007) observed that in IRN-resistant CRC cell lines,
significantly higher protein levels of HSPB1 were expressed.
In the present study, both HSPA1A andHSPB1were shown to
be highly induced following treatment with 5-FU, OX and
IRN, which could be prevented by prior siRNA-mediated si-
lencing. This knockdown of HSPB1was seen to sensitise cells
to both 5-FU and OX, yet sensitivity to IRN was not affected.
Silencing HSPA1A, on the other hand, did not sensitise cells
to 5-FU, OX or IRN. The results suggest that HSPB1 is more
important in the present system at conferring resistance to
these drugs, and are supported by findings from Sharma
et al. (2009) who show increased sensitivity to 5-FU following
siRNA silencing of HSPB1, and also DNAJB1 (Hsp40) in
hepatoma cells. OGX-427 is an anti-sense oligonucleotide
which targets HSPB1. Several clinical trials on OGX-427
for solid tumours have provided posit ive results
(OncoGenex 2016). The results reported in this study provide
future justification to examine the efficacy of this drug in
CRC.
HSPC1 inhibition in future CRC therapy
Despite the excitement surrounding HSPC1 inhibitors as
means of overcoming chemoresistance and targeting tumour
evolvability, resistance to these inhibitors has been observed.
Acquired resistance to geldanamycin derivates has been pro-
posed by some investigators to be due to a decrease in levels
of NAD(P)H:quinone oxidoreductase 1 (NQO1) (Kelland
et al. 1999; Guo et al. 2005; Gaspar et al. 2009). NVP-
AUY922 is thought to be more useful in these cases as it is
not reliant on NQO1 for its toxic effects. A study into HSPC1
inhibitor sensitivity in lung cancer cells with ALK re-
arrangement showed that NQO1 expression was not associat-
ed with acquired resistance to 17-DMAG, and rather, it is the
induction of the multidrug resistant protein, P-glycoprotein
that confers resistance in these cells (Kim et al. 2015). These
findings highlight the different mechanistic actions of these
drugs despite similar HSPC1 N-terminal inhibition and sug-
gest that further mechanisms may be discovered that will ex-
plain resistance to NVP-AUY922.
Client protein activation by HSPC1 involves a plethora of
co-chaperones including Aha1. Binding of Aha1 to HSCP1 is
essential as an activator of HSPC1’s ATPase activity (Lotz
et al. 2003). Studies have demonstrated that Aha1 is essential
in helping cells to overcome stressful conditions especially
when HSPC1 levels are low, and Aha1 expression influences
the activity of many oncogenic proteins including C-RAF,
MEK1/2 and ERK1/2 (Holmes et al. 2008). Furthermore,
treatment with 17-AAG results in sustained upregulation of
Aha1 and silencing of Aha1 sensitises cells to 17-AAG treat-
ment. NVP-AUY922 has also been shown to affect the levels
of Aha1, and basal levels of Aha1 were found to be higher in
NVP-AUY922-resistant non-small-cell lung cancer (NSCLC)
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cell lines than sensitive NSCLC cell lines (Garon et al. 2013).
Future analysis of Aha1 may help to understand the mecha-
nisms behind NVP-AUY922 resistance in these cells.
Clinical trial results had identified certain groups of pa-
tients who are more susceptible to HSPC1 inhibitions. A
phase II trial in refractory metastatic colorectal cancer patients
suggested that 53% of those who reported stable disease had
KRAS-mutated tumour (Cercek et al. 2014). This is also sup-
ported by in vitro study showing that KRAS mutant tumours
are more susceptible to HSPC1 inhibitions via degradation of
STK33 (Azoitei et al. 2012). Two separate clinical trials in-
vestigating HSPC1 inhibitors in NSCLC patients have also
identified those with ALK re-arrangement to be more suscep-
tible to HSPC1 inhibitors (Sequist et al. 2010; Socinski et al.
2013). In contrast, trial investigating HSPC1 inhibitor in
HER-2 (a sensitive client protein of HSPC1) positive breast
cancer in 26 patients did not show any confirmed responses
(Modi et al. 2013). The message thus far is consistently show-
ing that HSPC1 inhibitors will likely be beneficial in a select-
ed, susceptible group of patients. Moving forward, trials in-
volving HSPC1 inhibitors will need to incorporate, either pro-
spectively or retrospectively, steps to identify biomarkers that
will identify susceptible patients.
Limitations
This study investigated the effects of three N-terminal HSPC1
inhibitors, which are 17-DMAG, NVP-HSP990 and NVP-
AUY922, which for several years have been tested in a num-
ber of clinical trials on a variety of cancer types (Hong et al.
2013). Since the completion of this study, newer inhibitors
such as r e so rc ino l de r iva t i ve s and C- t e rmina l
HSPC1inhibitors and also new strategies to target HSPC1
co-chaperones or client-protein interactions have begun to
emerge as alternative routes to target HSPC1 activity
(Shrestha et al. 2016). Nevertheless, this does not make the
results from this study any less important, especially when
considering HSPC1 inhibition in the clinical setting. The find-
ings that the same cell type responded to the three N-terminal
HSPC1 inhibitors differently is especially important in this
context as it highlights that failure to achieve HSPC1 inhibi-
tion in a given patient using one inhibitor may be overcome by
use of another similar drug. The results also highlight the
importance of developing a model that can perhaps identify
which type of inhibitor is most likely to work in an individual
patient in the pre-clinical setting.
Another limitation is the use of a single cell line in this
study. It could be argued that this may limit the strength of
the findings. However, HSPC1 inhibition has been studied in
other CRC cell lines, also with mixed results in terms of cell
sensitivity and potentiation of other chemoagents (Tse et al.
2009; Powers et al. 2008; He et al. 2014). By using a single
cell line to mimic a single patient, this study was able to
demonstrate the different effects of inhibiting HSPC1 and
the effect of combining these therapies with traditional che-
motherapeutic agents. This direct comparison ofmultiple ther-
apies in different combinations, using the same cell type, has
not been performed before. The results show that given the
ubiquitous and multifunctional nature of HSPs in humans,
there may be many ways to target HSPs in a patient that will
have similar desired effect. Moving forward, the challenge lies
in finding the most suitable method for each patient.
Conclusion
HSPC1 inhibitors are effective anti-cancer agents; however,
their clinical applicability thus far is somewhat limited. This
study showed even amongst N-terminal inhibitors that there
are distinct differences in effects on CRC cells. In a clinical
setting, this could mean that a single patient may show sensi-
tivity to one inhibitor but resistance to another. Certainly, the
results do indicate that dosing of NVP-AUY922 may need
careful consideration to ensure sustained activity, and future
clinical trials should put this into consideration. HSPC1 inhib-
itors also showed promise in potentiating current chemother-
apeutic agents for CRC. Targeting HSPC1 is likely to be most
effective in cancers where oncogenic drivers are sensitive cli-
ent proteins. Therefore, prior to initiation of a clinical trial, it
will be essential to identify a biomarker for sensitivity towards
HSPC1 inhibitors.
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